TSPO Deletion Reduces Cortical Spreading Depolarization in Mice

Understanding Cortical Spreading Depolarization in Neurological Disease

Cortical spreading depolarization (CSD) is a wave of intense but transient neuronal and glial depolarization implicated in the pathophysiology of migraine with aura, traumatic brain injury, and ischemic stroke [1, 2, 3]. This electrophysiological event is not benign; it can initiate a cascade of neuroinflammatory and neurovascular responses that contribute directly to lesion expansion and clinical worsening [4, 5, 6]. The process involves the activation of microglia and astrocytes, which release pro-inflammatory mediators that can disrupt the blood-brain barrier (BBB) [7, 8, 9]. Identifying the specific molecular mechanisms that govern CSD susceptibility and its damaging aftereffects is therefore a critical step toward developing new therapeutic interventions [10, 11]. A recent study provides new data on a mitochondrial protein that may influence these processes.

Translocator Protein 18 kDa: A Potential Modulator of CSD

A new investigation focuses on the role of translocator protein 18 kDa (TSPO), a protein located in the outer mitochondrial membrane. Because TSPO is known to participate in cellular metabolism and inflammation, particularly within glial cells, the researchers hypothesized it could modulate the brain's susceptibility to cortical spreading depolarization (CSD). This line of inquiry is clinically significant because the neurovascular and inflammatory responses triggered by CSD are known to worsen brain lesions in conditions like stroke and traumatic brain injury. Therefore, understanding the molecular drivers of CSD and its sequelae is essential for designing therapies that might limit the extent of neurological damage in affected patients.

Investigating TSPO's Role in CSD Generation

To test their hypothesis, the researchers employed a TSPO-knockout mouse model, allowing for a direct comparison against wild-type controls. The first step was a careful histological analysis to confirm that the brains of the genetically modified mice were structurally normal. This analysis verified that the TSPO-knockout mice developed the expected six-layered cortical structure with neuronal and glial cell populations comparable to wild-type mice, ensuring that any observed differences in CSD susceptibility would be attributable to the absence of TSPO, not to underlying developmental brain abnormalities. Following this validation, the team used in vivo electrophysiology, a technique for measuring electrical activity directly in the brains of anesthetized animals, to assess the generation of CSD. The central finding was that mice with TSPO deletion had a reduced number of CSD events compared with the control group. This result provides direct evidence that TSPO is involved in modulating the brain's susceptibility to these pathological electrical waves.

Impact on Inflammation and Blood-Brain Barrier Integrity

The investigation also examined the downstream consequences of TSPO deletion on the brain's response to cortical spreading depolarization (CSD). The authors found that the reduction in CSD events was linked to an impaired induction of key inflammatory genes, including interleukin-1 beta (IL-1β), cyclooxygenase-2 (Cox2), and chemokine (C-C motif) ligand 2 (Ccl2). The diminished expression of these well-known pro-inflammatory mediators suggests that TSPO's presence is required for the full inflammatory cascade that typically follows a CSD event. Furthermore, the study demonstrated that TSPO gene deletion conferred a protective effect on CSD-induced disruption of the blood-brain barrier. This was quantified by measuring the leakage of a dye, Evans blue, from the bloodstream into the brain tissue. The researchers observed less extravasation of the Evans blue administered systemically in the knockout mice, indicating a more intact and less permeable barrier. Taken together, these findings identify a role for TSPO in modulating both the inflammatory and neurovascular damage that are sequelae of CSD, highlighting it as a potential target for therapies aimed at mitigating CSD-related pathology.

References

1. Hattori M, Zhang Q, Handa T, et al. Alteration of the cortical spreading depolarization in the mouse defective in translocator protein 18 kDa.. Brain research. 2026. doi:10.1016/j.brainres.2026.150386

2. Soylu KO, Yemişçi M, Karataş H. The link between spreading depolarization and innate immunity in the central nervous system. The Journal of Headache and Pain. 2025. doi:10.1186/s10194-024-01938-5

3. Hadjikhani N, Vincent M. Neuroimaging clues of migraine aura. The Journal of Headache and Pain. 2019. doi:10.1186/s10194-019-0983-2

4. Dalkara T, Kaya Ζ, Erdener ŞE. Unraveling the interplay of neuroinflammatory signaling between parenchymal and meningeal cells in migraine headache. The Journal of Headache and Pain. 2024. doi:10.1186/s10194-024-01827-x

5. Hostiuc S, Rusu M. The Dynamics of Neuroinflammation in Traumatic Brain Injury: Molecular Markers Useful for Establishing the Post-Traumatic Interval in Forensic Practice. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27042049

6. Solar P, Zamani A, Lakatosová K, Joukal M. The blood–brain barrier and the neurovascular unit in subarachnoid hemorrhage: molecular events and potential treatments. Fluids and Barriers of the CNS. 2022. doi:10.1186/s12987-022-00312-4

7. Rodkin S, Gasanov M, Tushev A, et al. The Dual Role of Connexins in Stroke, Neurotrauma, Neurodegenerative and Psychiatric Disorders: A Global Systematic Review. Molecules. 2026. doi:10.3390/molecules31081341

8. Onat F, Andersson M, Çarçak N. The Role of Glial Cells in the Pathophysiology of Epilepsy. Cells. 2025. doi:10.3390/cells14020094

9. Aranda-Abreu GE, Rojas-Durán F, Hernández-Aguilar ME, Herrera-Covarrubias, Tlapa-Monge LR, Gutiérrez S. Alzheimer’s Disease as a Disorder of Neuroimmune Dysregulation. Neurology International. 2026. doi:10.3390/neurolint18020037

10. Rehman S, Nadeem A, Akram U, et al. Molecular Mechanisms of Ischemic Stroke: A Review Integrating Clinical Imaging and Therapeutic Perspectives. Biomedicines. 2024. doi:10.3390/biomedicines12040812

11. Sharma P, Sawaya M, Dumitrescu AM, et al. Novel neurotherapeutic targets for substance use disorders: Neuroplasticity, neuroinflammation, gasotransmitters and non-canonical organ systems. Neurotherapeutics. 2025. doi:10.1016/j.neurot.2025.e00770